Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy E Davidson

Showing results (271-280 of 285) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Nature Communications|November 10, 2019
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Nature Communications|January 31, 2020
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer StudyRoisin M Connolly, Huili Li, Rachel C Jankowitz, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFTPrudence A Francis, Gini F Fleming, István Láng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2026
Impact of Tamoxifen Only after Lumpectomy for "Good Risk" Duct Carcinoma in Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 TrialsJean L Wright, Jennifer Moughan, Wendy A Woodward, et al.
JAMA Oncology|August 15, 2024
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast CancerRuth M O'Regan, Yi Zhang, Gini F Fleming, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The New England Journal of Medicine|December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Pageof 29

Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Nature Communications|November 10, 2019
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Nature Communications|January 31, 2020
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer StudyRoisin M Connolly, Huili Li, Rachel C Jankowitz, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFTPrudence A Francis, Gini F Fleming, István Láng, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2026
Impact of Tamoxifen Only after Lumpectomy for "Good Risk" Duct Carcinoma in Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 TrialsJean L Wright, Jennifer Moughan, Wendy A Woodward, et al.
JAMA Oncology|August 15, 2024
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast CancerRuth M O'Regan, Yi Zhang, Gini F Fleming, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The New England Journal of Medicine|December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Pageof 29